Time is limited! Fill out the form on this page to see if you qualify.
An advocate or attorney will contact you within minutes for your free consultation.
No fees unless you are awarded compensation!
Actemra (tocilizumab) is a prescription immunosuppressant drug that’s either injected weekly or taken intravenously once per month to treat:
Actemra belongs to a newer class of biological therapy drugs called IL-6 inhibitors. They keep the body from producing too much interleukin-6 (IL-6) protein, which causes severe inflammation. Roche’s subsidiary company, Genentech, developed Actemra to treat patients who don’t respond well to TNFi drugs like Humira, Enbrel and Remicade.
Since 2010, over 1,000 patients have died after taking Actemra, according to FDA adverse event reports. In fact, several clinical trials and medical studies show Actemra has similar complication rates as competing drugs Enbrel, Humira and Remicade. While the competing drugs’ labels warn patients about stroke, heart attack, lung disease and pancreatitis risks, Actemra’s does not. As a result, thousands of patients with potentially fatal Actemra complications may now qualify for a cash settlement.
